Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

Launched by MAYO CLINIC · Sep 2, 2022

Keywords

ClinConnect Summary

This clinical trial is studying changes in DNA and proteins in blood and tissue samples from patients with aggressive metastatic cancer, which is cancer that has spread to other parts of the body. The goal is to identify potential markers that could help diagnose these types of cancer and discover new treatments. By examining samples taken during surgeries or biopsies, researchers hope to learn more about how cancer affects the body and find specific characteristics in tumors that could guide future therapies.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of cancer. You should also be a suitable candidate for a biopsy or surgery to obtain tissue samples. Before joining, you'll need to provide written consent, meaning you understand the study and agree to participate. If you are eligible, you can expect to have your blood and tissue samples analyzed in the lab, which may help doctors better understand your cancer and improve treatment options. It's important to note that there are specific conditions that may prevent participation, such as certain health issues or if your tumor cannot be safely accessed for a biopsy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients (or the legally authorized representative/guardian signing on behalf of the participant) must understand and provide written informed consent prior to initiation of any study-specific procedures
• • \>= 18 years of age
• • Patients must have a diagnosis of confirmed malignancy
• • Patient is a good medical candidate for a standard of care biopsy or surgical procedure to obtain tissue or has archival tissue available for analysis
• Exclusion Criteria:
• • Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
• • Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use
• * Biopsy must not be considered to be more than minimal risk to the patient. Contraindications to percutaneous biopsy:
• • Significant coagulopathy that cannot be adequately corrected
• • Severely compromised cardiopulmonary function or hemodynamic instability
• • Lack of a safe pathway to the lesion
• • Inability of the patient to cooperate with, or to be positioned for, the procedure